Home / Markets / Industries / Health Care
Tuesday, February 09, 2010
Novartis Licenses Hepatitis C Drug
By Steve Goldstein
MarketWatch Pulse
LONDON -- Novartis said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease. It's been licensed from Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, under an agreement which gives Novartis exclusive worldwide development and marketing rights outside of Japan. Under the terms of the agreement, Novartis will make an upfront payment to Debiopharm, and Debiopharm will be eligible for milestone payments, and for royalties on future sales of Debio 025, if it is approved.
Copyright © 2010 MarketWatch, Inc.
Fox Business Video
-
-
New Jersey Nets CEO on Locatio...
-
Mar 11, 2010
Nets making money in Brooklyn
-
-
-
SEIU on Interest Rate Swap Deals
-
Mar 11, 2010
Citi's getting slammed by interest rate swap deals
-
-
-
Bulls and Bears Play Tug of War
-
Mar 11, 2010
Breaking down market moves
-
-
-
Pandit to Remain at Citi
-
Mar 11, 2010
Gasparino: No pressure for Pandit to leave
-
-
-
How High Will Your Taxes Go?
-
Mar 11, 2010
22 States have raised taxes from recession
-
Last 5 Stocks
- Ticker
- Company
- Price
- Change